Advanced Oncotherapy (AVO) Selects RayStation for the First LIGHT System in Central London
Published: Jul 05, 2018
STOCKHOLM, July 5, 2018 /PRNewswire/ --
The UK based developer of next generation proton therapy technology, Advanced Oncotherapy plc (AVO), has selected RayStation as its treatment planning system for the first LIGHT (Linac Image Guided Hadron Technology) system at the proton therapy facility under construction at Harley Street in central London. Users at the clinic will have access to the full spectrum of RayStation's functionality.
AVO and RaySearch have entered into a collaboration agreement to support the LIGHT system fully. The LIGHT system is a modular proton therapy system based on innovative technology, developed in a collaboration between the TERA project and CERN in Geneva, Switzerland. The heart of the system consists of a treatment room integrated with a linear accelerator, which accelerates protons to energies suitable for radiation therapy of cancer. The entire system is designed for cost effectiveness and low maintenance and has several key features, such as multiple spot sizes and fast energy switching time.
The order of RayStation for Harley street gives the users access to the full spectrum of RayStation's functionality, including the fast proton Monte Carlo dose engine, robust 4D optimization, LET driven optimization, deformable registration, dose accumulation, plan adaptation, multi-criteria optimization and Plan Explorer for automatic plan generation.
Nicolas Serandour, AVO Chief Executive Officer, says: "We are thrilled to collaborate with RaySearch. RaySearch has established themselves as the technology of choice for light ion therapy treatment planning. As we bring our advanced particle therapy treatment technology into the field, it makes sense to have the most advanced treatment planning capability to complement it. We believe the synergetic combination is significant for optimizing patient care at our first proton therapy center in the renowned medical practice area of Harley Street, London."
Dr Jonathan Farr, AVO's Director of Medical Physics, says "Our linac based LIGHT system includes many special features requiring new treatment planning development and customization. RaySearch is uniquely poised to perform this and intends to deliver updates to their RayStation product supporting LIGHT advanced capabilities - thereby extending the accuracy and versatility of proton therapy."
Johan Löf, CEO RaySearch, says: "AVO's LIGHT system is a state-of-the-art solution for proton therapy, and we are very pleased that the RayStation treatment planning system was chosen by AVO. The LIGHT system has several advanced capabilities and RayStation will fully support this groundbreaking innovation. This new collaboration is in line with RaySearch's ambition to provide full planning support for most treatment delivery machines on the market. The possibility to plan all types of radiation treatments on one common platform allows clinicians to select the optimal treatment machine and delivery technique for every patient, which in turn leads to better treatment quality and more effective use of available resources."
The majority of this order has been delivered and will generate revenue in the second quarter of 2018. The remaining order value will generate revenue during the coming 36 months.
About Advanced Oncotherapy
Advanced Oncotherapy plc (AVO) is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team Applications of Detectors and Accelerators to Medicine (ADAM SA), based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control. Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment-related side effects. Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. For more information go to: www.avoplc.com
RayStation integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system and the RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. RaySearch's software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact::
President and CEO,
RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510-530-00
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
http://mb.cision.com/Main/1102/2568998/873685.pdf PDF http://news.cision.com/raysearch-laboratories/i/avo-cision-283x142px,c2448514 AVO-Cision 283x142px
SOURCE RaySearch Laboratories
Company Codes: Berlin:27R, Bloomberg:RAYB@SS, ISIN:SE0000135485, OTC-PINK:RSLBF, RICS:RAYB.ST, Stockholm:RAYB, Frankfurt:27R